Prohibits 340B program entities from using drug discount savings to pay for gender-altering surgeries or hormone treatments for transgender individuals, so less access to such care.
A covered entity participating in the program under this section may not use any funds derived from the difference between the 340B ceiling price and the actual acquisition cost of covered outpatient drugs to pay for services described.
✓ Quote verified word for word in the bill text
Introduced (completed)
Committee
Passed one chamber
Passed both
President
Law
Stage: Committee · step 2 of 6
Last action
2025-03-18: Referred to the House Committee on Energy and Commerce.
Why the model tagged it this way: The bill adds a prohibition in the 340B drug discount program barring covered entities from using program-derived savings to fund gender-transition surgeries or hormone treatments, directly restricting access to transgender healthcare services.
Related bills
S3206Transgender Health Care Access Act↑Expands transgender recognition & access Committee
S3011Prohibiting Abortion & Transgender Procedures on the Exchanges Act↓Restricts transgender recognition & access↓Restricts abortion access Committee